HRP20140611T1 - Inhibitori kinaze p70 s6 - Google Patents

Inhibitori kinaze p70 s6 Download PDF

Info

Publication number
HRP20140611T1
HRP20140611T1 HRP20140611AT HRP20140611T HRP20140611T1 HR P20140611 T1 HRP20140611 T1 HR P20140611T1 HR P20140611A T HRP20140611A T HR P20140611AT HR P20140611 T HRP20140611 T HR P20140611T HR P20140611 T1 HRP20140611 T1 HR P20140611T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
intended
trifluoromethyl
Prior art date
Application number
HRP20140611AT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L. Holst
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20140611T1 publication Critical patent/HRP20140611T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20140611AT 2007-05-11 2008-05-01 Inhibitori kinaze p70 s6 HRP20140611T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20140611T1 true HRP20140611T1 (hr) 2014-08-15

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140611AT HRP20140611T1 (hr) 2007-05-11 2008-05-01 Inhibitori kinaze p70 s6

Country Status (33)

Country Link
US (2) US8093383B2 (OSRAM)
EP (1) EP2148880B1 (OSRAM)
JP (1) JP5503532B2 (OSRAM)
KR (1) KR101088219B1 (OSRAM)
CN (1) CN101679439B (OSRAM)
AR (1) AR066344A1 (OSRAM)
AU (1) AU2008251692B2 (OSRAM)
BR (1) BRPI0811212A2 (OSRAM)
CA (1) CA2687265C (OSRAM)
CL (1) CL2008001230A1 (OSRAM)
CO (1) CO6241109A2 (OSRAM)
CR (1) CR11106A (OSRAM)
DK (1) DK2148880T3 (OSRAM)
DO (1) DOP2009000257A (OSRAM)
EA (1) EA016445B1 (OSRAM)
EC (1) ECSP099721A (OSRAM)
ES (1) ES2483726T3 (OSRAM)
GT (1) GT200900292A (OSRAM)
HR (1) HRP20140611T1 (OSRAM)
IL (1) IL201564A (OSRAM)
MA (1) MA31433B1 (OSRAM)
MX (1) MX2009012075A (OSRAM)
MY (1) MY154898A (OSRAM)
NZ (1) NZ580423A (OSRAM)
PE (1) PE20090887A1 (OSRAM)
PL (1) PL2148880T3 (OSRAM)
PT (1) PT2148880E (OSRAM)
RS (1) RS53451B (OSRAM)
SI (1) SI2148880T1 (OSRAM)
TN (1) TN2009000446A1 (OSRAM)
TW (1) TWI423805B (OSRAM)
UA (1) UA99284C2 (OSRAM)
WO (1) WO2008140947A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
CN102209539B (zh) * 2008-11-11 2013-06-12 伊莱利利公司 P70 s6激酶抑制剂和mtor抑制剂的组合治疗剂
BRPI0921888A2 (pt) 2008-11-11 2015-12-29 Lilly Co Eli terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
EP2396307B1 (en) 2009-02-11 2014-10-15 Merck Patent GmbH Novel amino azaheterocyclic carboxamides
EP2462141B1 (en) 2009-08-07 2017-09-27 Merck Patent GmbH Novel azaheterocyclic compounds
CN102574852B (zh) * 2009-10-23 2014-06-25 伊莱利利公司 Akt抑制剂
UA110697C2 (uk) 2010-02-03 2016-02-10 Сігнал Фармасьютікалз, Елелсі ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
ES2729754T3 (es) 2010-07-29 2019-11-06 Merck Patent Gmbh Carboxamidas azaheterocíclicas de aminas cíclicas
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EP2643313B9 (en) 2010-11-24 2017-02-22 Merck Patent GmbH Quinazoline carboxamide azetidines
US9145392B2 (en) * 2011-09-12 2015-09-29 Merck Patent Gmbh Imidazole amines as modulators of kinase activity
DK2755958T3 (en) 2011-09-12 2017-09-25 Merck Patent Gmbh AMINOPYRIMIDINE DERIVATIVES USED AS MODULATORS OF KINASE ACTIVITY
WO2014039714A2 (en) * 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2890288A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
CN105102435A (zh) 2012-11-16 2015-11-25 默克专利有限公司 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
CN105793254B (zh) 2012-11-29 2020-10-23 默克专利有限公司 氮杂喹唑啉羧酰胺衍生物
HK1218756A1 (zh) * 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
KR102242505B1 (ko) 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2733401C2 (ru) 2014-04-03 2020-10-01 Мерк Патент Гмбх Комбинации противораковых лекарств
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP5213229B2 (ja) * 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
MA31433B1 (fr) 2010-06-01
IL201564A0 (en) 2010-05-31
DK2148880T3 (da) 2014-06-16
HK1140767A1 (en) 2010-10-22
PT2148880E (pt) 2014-08-28
ECSP099721A (es) 2009-12-28
CA2687265A1 (en) 2008-11-20
MX2009012075A (es) 2009-11-19
US20120071490A1 (en) 2012-03-22
UA99284C2 (ru) 2012-08-10
PE20090887A1 (es) 2009-07-13
CA2687265C (en) 2012-12-04
KR101088219B1 (ko) 2011-11-30
CR11106A (es) 2010-04-12
EP2148880B1 (en) 2014-05-28
SI2148880T1 (sl) 2014-07-31
TWI423805B (zh) 2014-01-21
US20090163714A1 (en) 2009-06-25
MY154898A (en) 2015-08-28
CL2008001230A1 (es) 2009-05-22
EA016445B1 (ru) 2012-05-30
JP2010526814A (ja) 2010-08-05
KR20100005710A (ko) 2010-01-15
EA200971051A1 (ru) 2010-06-30
EP2148880A1 (en) 2010-02-03
CN101679439B (zh) 2013-09-11
ES2483726T3 (es) 2014-08-07
AU2008251692A1 (en) 2008-11-20
AR066344A1 (es) 2009-08-12
US8093383B2 (en) 2012-01-10
RS53451B (sr) 2014-12-31
IL201564A (en) 2014-08-31
JP5503532B2 (ja) 2014-05-28
CO6241109A2 (es) 2011-01-20
CN101679439A (zh) 2010-03-24
WO2008140947A1 (en) 2008-11-20
AU2008251692B2 (en) 2012-10-11
DOP2009000257A (es) 2010-03-31
GT200900292A (es) 2011-06-24
TN2009000446A1 (en) 2011-03-31
NZ580423A (en) 2012-02-24
BRPI0811212A2 (pt) 2014-10-29
PL2148880T3 (pl) 2014-10-31
TW200848053A (en) 2008-12-16

Similar Documents

Publication Publication Date Title
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
MY150519A (en) Imidazoquinolines with immuno-modulating properties
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
HRP20221154T1 (hr) Supstituirani pirazolo[1,5-a]piridinski spojevi kao inhibitori ret kinaze
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
SE0402735D0 (sv) Novel compounds
NZ605528A (en) Ip receptor agonist heterocyclic compounds
GEP20156267B (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NZ588994A (en) Phenyl and benzodioxinyl substituted indazoles derivatives
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
HRP20131051T1 (hr) Inhibitori proteinskih kinaza
AR092289A1 (es) Derivados de aminoquinazolina y sus sales y metodos de uso
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
PT1856045E (pt) Derivados do ácido indol-1-acético que possuem actividade antagonista de pgd2
CA2406392A1 (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
WO2005090336A8 (en) 2-propanol and 2-propylamine derivatives and their use as glucocorticoid ligands